Chongqing Zhifei Biological Products (300122.SZ): Recombinant Rotavirus Subunit Vaccine (Escherichia coli) Clinical Trial Application Accepted for Review

Chongqing Zhifei Biological Products (300122.SZ) announced that the company recently learned that the recombinant rotavirus subunit vaccine (Escherichia coli) developed by its wholly-owned subsidiary, Beijing Zhifei Lvzhu Biological Pharmaceutical Co., Ltd. (referred to as "Zhifei Lvzhu"), has received the Notice of Acceptance of Drug Clinical Trial Application from the National Medical Products Administration (Acceptance No.: CXSL2600643). Within 60 days from the date of acceptance, if no negative or challenging opinions are received from the drug review center, Zhifei Lvzhu can proceed with the clinical trial according to the submitted plan. The recombinant rotavirus subunit vaccine (Escherichia coli) developed by Zhifei Lvzhu is used to prevent acute gastroenteritis caused by rotavirus infection in infants and children. The acceptance of the clinical trial application for this vaccine is a result of the company's focus on innovative technologies and enhancement of core research and development capabilities. If this project progresses smoothly, it will further enrich the company's portfolio of vaccines for gastrointestinal infections, improve the company's product layout, and strengthen its market position.